It now includes oral GLP-1 drugs, amylin combinations, dual agonists, triple agonists, long-acting platforms, and differentiated assets designed for durability, tolerability, access, or broader metabolic indications
B., Jerome, D., & Yeung, J
The YpsoMate 1 and 2.25 mL autoinjectors already in use for various biologics, including GLP-1s have been redesigned to achieve a lower carbon footprint without requiring any changes to drug formulation, delivery protocols or device
doi: 10.1186/s13054-014-0701-z 36
GLP-1 release is activated by luminal intestinal chemosensors, which could be reached by peptides of different sizes, mixed with free amino acids
Potency: In animal studies, Dihexa has been shown to be millions of times more potent than BDNF (Brain-Derived Neurotrophic Factor) at stimulating synapse formation